Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Bright

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chemsuschem|September 25, 2019
Solvent Selection for Lignin Value Prior to PulpingThomas T Kwok, John R Bright, Soor R Vora, et al.
The Journal of Urology|March 1, 2022
Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate CancerJohn R Bright, Rosina T Lis, Anson T Ku, et al.
The Prostate|May 6, 2024
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasisJuanJuan Yin, Asha Daryanani, Fan Lu, et al.
Nature Communications|February 15, 2020
A case report of multiple primary prostate tumors with differential drug sensitivityScott Wilkinson, Stephanie A Harmon, Nicholas T Terrigino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
European Urology|March 31, 2021
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal TherapyScott Wilkinson, Huihui Ye, Fatima Karzai, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate CancerAdam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chemsuschem|September 25, 2019
Solvent Selection for Lignin Value Prior to PulpingThomas T Kwok, John R Bright, Soor R Vora, et al.
The Journal of Urology|March 1, 2022
Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate CancerJohn R Bright, Rosina T Lis, Anson T Ku, et al.
The Prostate|May 6, 2024
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasisJuanJuan Yin, Asha Daryanani, Fan Lu, et al.
Nature Communications|February 15, 2020
A case report of multiple primary prostate tumors with differential drug sensitivityScott Wilkinson, Stephanie A Harmon, Nicholas T Terrigino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2020
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic ResponseFatima Karzai, Stephanie M Walker, Scott Wilkinson, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
European Urology|March 31, 2021
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal TherapyScott Wilkinson, Huihui Ye, Fatima Karzai, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
The Journal of Clinical Investigation|September 4, 2025
Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibitionScott Wilkinson, Anson T Ku, Rosina T Lis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate CancerAdam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Pageof 1